Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01314443 · ClinicalTrials.gov registry record · Phase 1

Impact of Smoking Cessation and γ-Tocopherol to Restore Vascular Endothelial Function

A Phase 1 study, sponsored by University of Connecticut.

Completed
Registry status
Phase 1
Development phase
67
Enrollment target

NCT01314443: Completed Phase 1 study, sponsored by University of Connecticut.

NCT01314443 is a Phase 1 study that has completed, run by University of Connecticut. The registered enrollment target is 67 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (12% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01314443, a Phase 1 study, has completed, sponsored by University of Connecticut.

COMPLETED
Registry status
Phase 1
Development phase
67 participants
Enrollment target

Study Summary

Cigarette smoking is a significant risk factor for cardiovascular disease (CVD) and is the leading cause of premature mortality in the US. The detrimental effects of smoking on vascular dysfunction are attributed to the effects of smoke itself and the inflammatory responses it induces. Smoking cessation restores vascular function by alleviating these stress responses. However, smoking cessation with nicotine replacement therapy (NRT), the prevailing approach to mitigate tobacco dependence, fails to allow full restoration of vascular function. Thus, a critical public health problem exists to understand how NRT prevents restoration of vascular function and how these NRT-mediated impairments can be overcome by using gamma-tocopherol (g-T) as an innovative co-therapy. The objective of this study is to conduct a clinical intervention trial that aims to reduce CVD risk by defining how smoking cessation and g-T restore vascular function. The hypothesis is that smoking cessation and dietary g-T supplementation will synergistically restore smoking-induced impairments in vascular function by ameliorating oxidative/nitrosative stress responses, and that g-T will facilitate full restoration of vascular function otherwise precluded by NRT. A placebo-controlled, g-T intervention study will be conducted in cigarette smokers undergoing nicotine-free or NRT smoking cessation. Prior to and after 24 h and 7 days of placebo or g-T administration, vascular function will be evaluated using a non-invasive ultrasound technique and an array of antioxidants and biomarkers for vascular inflammation and oxidative/nitrosative stress responses will be assessed. Collectively, these studies will help identify how vascular function is regulated in individuals undergoing smoking cessation, and whether g-T can be used as a strategy to better improve vascular function during smoking cessation.

Primary Outcome

Flow-mediated dilation (FMD) of the brachial artery is measured to assess vascular endothelial function. FMD is obtained by monitoring change in vessel diameter before and after brachial artery occlusion with a blood pressure cuff. The unit of FMD is % and is calculated using the following equation: FMD = \[(peak dilation at post occlusion - vessel diameter at preocclusion)/vessel diameter at preocclusion\]\*100.

Interventions

  • OTHER Placebo
  • BEHAVIORAL Smoking cessation
  • OTHER Nicotine Replacement Therapy (NRT)
  • DIETARY_SUPPLEMENT Gamma-Tocopherol

Trial Details

FieldValue
Enrollment Target 67 participants
Start Date 2011-01
Est. Completion 2014-12
Phase Phase 1
University of Connecticut

107 total trials

What the finished NCT01314443 record still lists

NCT01314443 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 67 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (12% higher).

The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.

NCT01314443 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01314443 about?

NCT01314443 is a clinical study titled "Impact of Smoking Cessation and γ-Tocopherol to Restore Vascular Endothelial Function". Cigarette smoking is a significant risk factor for cardiovascular disease (CVD) and is the leading cause of premature mortality in the US. The detrimental effects of smoking on vascular dysfunction are attributed to the effects of smoke itself and the inflammatory responses it induces. Smoking cessa...

What is the current status of trial NCT01314443?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 67 participants. The study started on 2011-01. Estimated completion is 2014-12.

What interventions are being tested in trial NCT01314443?

The interventions under investigation include: Placebo (OTHER), Smoking cessation (BEHAVIORAL), Nicotine Replacement Therapy (NRT) (OTHER), Gamma-Tocopherol (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT01314443?

This trial is sponsored by University of Connecticut, which has 107 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01314443's enrollment target sits among peer trials

67 782nd of 2000 higher than 1,215 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03213002 · 67 participants · Phase 1

    Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM

  • NCT04115163 · 67 participants · Phase 2

    Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer

  • NCT04315324 · 67 participants · Phase 1

    Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)

  • NCT04532424 · 67 participants · NA

    Transcranial Magnetic Stimulation for Restricted and Repetitive Behavior in ASD

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01314443, the US trial registry maintained by the National Library of Medicine. NCT01314443 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.